Search

Your search keyword '"Averna M"' showing total 959 results

Search Constraints

Start Over You searched for: Author "Averna M" Remove constraint Author: "Averna M"
959 results on '"Averna M"'

Search Results

1. Come superare le barriere all'implementazione delle strategie di prevenzione e cura della malattia cardiovascolare aterosclerotica mediante terapia ipolipemizzante

5. Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome (FCS): Data from the LOCHNES study

6. Novel missense variants in the LMF1 gene: Identification by next generation sequencing and functional characterization

7. The contemporary management of patients with homozygous familial hypercholesterolemia: The experience of the Italian Lipigen registry and a systematic review of the literature

11. New and Emerging Therapies for Dyslipidemia

12. The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group

13. Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

14. Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group

15. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

16. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study

19. Comparison of two polygenic risk score to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects: Polygenic hypocholesterolemias

20. Uncommon presentation of Cholesteryl Ester Storage Disease (CESD): Description of a case and genetic characterization by next generation sequencing

26. Coronary artery calcium is strongly associated with pulse wave velocity and LDL-cholesterol burden in patients with familial hypercholesterolemia

27. Post prandial metabolism of lipoproteins in familial chylomicronemia patients treated with lomitapide and tiparvovec

30. Next generation sequencing in severe hypertrigliceridemia: Identification of a novel nonsense mutation of CREB3L3 gene

31. Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia

32. Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations

35. Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts

36. Lipid and apolipoprotein in cord blood

40. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis

41. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study

43. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study

44. Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study (Internal and Emergency Medicine, (2018), 13, 5, (651-660), 10.1007/s11739-018-1835-9)

46. Mutation in candidate genes account for a small minority of hypobetalipoproteinemias and NGS analysis support polygenicity in mutation-negative patients

47. PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides. An in vitro study

48. Molecular characterization of patients with and without coronary artery disease with “extreme LDL-C phenotypes”

Catalog

Books, media, physical & digital resources